Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesProfound Medical Corp

Profound Medical Corp

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
10.03 CAD 0.26 ( 2.66%)
Last update at 2026-11-04T16:47:00Z
VOLUME
46923
Market Cap
338.98M

Momentum Score

…

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.65
Low
10.20
High
52 Week Price Range
5.23
Low
12.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Profound Medical develops MRI-guided transurethral focused-ultrasound systems for targeted thermal ablation of prostate tissue. Long-term growth may be supported by aging populations, a shift to minimally invasive prostate treatments, expanding clinical evidence and growth of its installed base. Investors may find it attractive because the platform offers precise, organ-sparing therapy that could displace some surgery or radiation if adoption and reimbursement improve.

Key risks include a limited commercial track record, adoption and reimbursement hurdles, competition from established prostate therapies, and execution and financing risk when scaling the business.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
9.77
Dividend Yield
-
Revenue TTM
16.10M
Revenue Per Share
0.53
Gross Profit TTM
11.39M
Debt / Equity
0.07
ROE
-67.11%
Net Debt
-75.41M
ROCE
-31.20%
Diluted EPS TTM
-1.94

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -59.13M -27.82M -28.70M -28.38M -30.59M
Net income -59.48M -27.82M -28.57M -28.67M -30.70M
Selling general administrative 32.05M 23.13M 9.17M 9.46M 10.31M
Selling and marketing expenses - - 9.45M 8.47M 7.65M
Gross profit 15.92M 7.04M 4.38M 3.02M 2.95M
Reconciled depreciation 0.56M 0.94M 1.15M 1.60M 1.88M
Ebit -57.64M -33.06M -27.93M -29.60M -30.29M
Ebitda -56.86M -32.13M -27.00M -25.47M -28.41M
Depreciation and amortization 0.78M 0.94M 0.93M 4.13M 1.88M
Operating income -57.64M -33.06M -28.62M -29.60M -30.29M
Other operating expenses 80.14M 43.74M 35.81M 36.28M 37.16M
Interest expense - - 0.77M 0.17M 0.30M
Tax provision 0.25M -0.00M -0.13M 0.29M 0.10M
Interest income - 5.24M 1.64M 3.45M 0.14M
Net interest income 1.07M 1.44M 0.73M 0.92M -0.31M
Income tax expense 0.35M -0.00M -0.13M 0.29M 0.10M
Total revenue 22.49M 10.68M 7.20M 6.68M 6.87M
Total operating expenses 73.56M 40.10M 33.00M 32.62M 33.24M
Cost of revenue 6.57M 3.64M 2.82M 3.66M 3.92M
Total other income expense net -1.49M 5.24M -0.08M 1.22M -0.30M
Net income from continuing ops -42.57M -27.82M -28.57M -28.67M -30.70M
Net income applicable to common shares - -27.82M -28.32M -28.67M -30.70M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 193.10M 70.23M 43.91M 64.42M 86.78M
Intangible assets 0.19M 0.26M 0.49M 0.68M 1.44M
Other current assets 3.94M - 1.41M 1.22M 1.15M
Total liab 102.04M 9.81M 12.73M 12.42M 6.16M
Total stockholder equity 91.06M 60.42M 31.18M 52.00M 80.62M
Other current liab 5.07M 0.33M - 0.92M 0.25M
Common stock 443.90M - 217.39M 205.82M 219.58M
Capital stock 323.84M 281.55M 217.39M 205.82M 219.58M
Retained earnings -394.42M -245.17M -217.93M -189.36M -160.69M
Other liab - - - 0.76M 0.88M
Good will - - - 0.00M 2.69M
Other assets - - - - 3.62M
Cash 81.87M 54.91M 26.21M 46.52M 67.15M
Total current liabilities 8.33M 6.57M 6.37M 4.18M 4.16M
Current deferred revenue 0.61M - 0.72M 0.47M 0.48M
Net debt -75.41M - -18.27M -38.29M -65.78M
Short term debt 0.50M - 2.36M 0.76M 0.25M
Short long term debt - 1.74M 2.10M 0.52M -
Short long term debt total 6.46M - 7.94M 8.23M 1.38M
Other stockholder equity 34.69M - 19.69M 18.70M 16.99M
Property plant equipment - - - 1.72M 1.90M
Total current assets 104.30M 69.06M 41.90M 62.02M 77.12M
Net tangible assets - - - 51.32M 76.49M
Net receivables 7.20M 6.58M 7.29M 6.34M 1.41M
Long term debt 4.50M 2.92M 5.00M 6.65M -
Inventory 11.29M 5.80M 6.99M 7.94M 7.41M
Accounts payable 2.14M 1.32M 3.28M 2.03M 3.18M
Accumulated other comprehensive income 6.89M - 12.03M 16.84M 4.75M
Non currrent assets other - - - - 3.62M
Non current assets total 88.80M 1.17M 2.02M 2.40M 9.65M
Capital lease obligations 0.21M 0.46M 0.84M 1.06M 1.38M
Long term debt total - - - 7.47M 1.13M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - 0.00M -0.59M
Change to liabilities - - - -0.57M -0.36M
Total cashflows from investing activities -0.34M - - 0.00M -0.59M
Net borrowings -0.29M -2.56M -0.91M 6.92M -0.39M
Total cash from financing activities 57.48M 54.70M 1.46M 7.03M 5.95M
Change to operating activities - - - -2.09M -0.01M
Net income -59.48M -27.82M -28.32M -28.67M -30.70M
Change in cash 2.89M 28.70M -20.30M -20.64M -16.76M
Begin period cash flow 78.97M 26.21M 46.52M 67.15M 83.91M
End period cash flow 81.87M 54.91M 26.21M 46.52M 67.15M
Total cash from operating activities -53.39M -23.45M -22.61M -25.80M -22.36M
Issuance of capital stock 42.44M 62.11M 0.00M - 0.00M
Depreciation 0.78M 0.94M 1.15M 1.60M 1.88M
Change to inventory -3.94M 0.66M 0.35M -1.86M -2.49M
Change to account receivables -0.24M 0.19M -1.41M -1.42M 2.00M
Sale purchase of stock - 62.15M 2.67M 0.26M 6.43M
Other cashflows from financing activities - -4.85M 2.67M 7.39M 6.33M
Change to netincome - - - 6.89M 7.34M
Capital expenditures 0.25M 0.00M 0.00M 0.00M 0.59M
Change in working capital -2.39M 0.59M 0.54M -5.63M -0.88M
Stock based compensation 5.49M 2.58M 3.42M 4.24M 7.21M
Other non cash items 7.71M 0.26M 0.38M 2.66M 0.13M
Free cash flow -53.63M -23.45M -22.30M -25.80M -22.95M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PRN
Profound Medical Corp		 0.26
2.66%		 10.03 - - 21.06 3.72 11.94 -7.93

Profile*

Profound Medical Corp

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5

647 476 1350

https://www.profoundmedical.com

162

Name Title Year Born
Dr. Arun Swarup Menawat MBA, Ph.D. Chairman & CEO 1955
Mr. Rashed Dewan Chief Financial Officer 1968
Dr. Mathieu Burtnyk Sr. VP of Product Leader TULSA-PRO 1982
Mr. Stephen Kilmer Investor Relations NA
Mr. Hartmut Warnken Chief Commercial Officer of OUS NA
Mr. Jacques F. Cornet Sr. VP & Product Leader Sonalleve 1956
Mr. Michael Mydra VP & Head of Global Market Access NA
Mr. Abbey Goodman Chief Commercial Officer of US NA
Mr. Matthew Sobczyk C.A., CPA Assistant Corp. Controller NA
Mr. Levant Tinaz Software Developer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 29.99
+13.13%
AP-UN
CAD 4.19
+12.94%
ARTG
CAD 39.66
+12.93%
BZ
CAD 4.14
+10.99%
FFH
CAD 2759.48
+10.87%
DRUG
CAD 27.12
-26.86%
HUT
CAD 69.10
-22.27%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.85
-14.43%
MOON
CAD 4.09
-12.79%

Equity Sectors*

  • Basic Materials

    +3.69%

  • Communication Services

    +2.61%

  • Consumer Cyclical

    +2.96%

  • Consumer Defensive

    +1.11%

  • Energy

    -5.01%

  • Financial Services

    +2.20%

  • Healthcare

    -0.56%

  • Industrials

    -0.73%

  • Real Estate

    +1.90%

  • Technology

    +0.05%

  • Utilities

    +1.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…